樂觀
$15.83
情境價格
$13.970
-0.080 (-0.57%)收盤時
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

InMode Anticipates Q3 2026 Financial Results Release

InMode Launches Morpheus8 Cool Technology

Global Medical Aesthetics Market Poised for Significant Growth

Global Medical Aesthetics Market Poised for Significant Growth

InMode Reports Stable Q2 2026 Financial Results Amid Market Challenges
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).
InMode Ltd is currently a hold. The stock is priced at $14.16, which is below the analyst price target of $17, indicating potential upside. However, the RSI is at 41.68, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the forward P/E ratio of 9.99 indicates it is undervalued compared to the market, but the recent 1-year change of -11.56% raises concerns about its performance. The main risk is the ongoing evaluation of the acquisition bid, which could lead to volatility in the stock price.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。